We investigated the rate , outcomes , and predictors of ICH in 14 264 patients with atrial fibrillation from Rivaroxaban Once Daily , Oral , Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation ( ROCKET AF ) .